MIT engineers have developed a new nanoparticle that can protect a vaccine long enough to generate a strong immune response on mucosal surfaces far from the vaccination site.
GE Healthcare Life Sciences has agreed to build a modular biopharmaceutical factory in China for JHL Biotech, which could be a model for ways to grow local manufacturing in emerging markets.
The US Department of Health and Human Services (HHS) says it is buying cell lines to manufacture anthrax antitoxins on top of its $196m (€145m) deal with GlaxoSmithKline to stockpile Raxibacumab.
Kemwell says it intends to open the Indian market to contract biomanufacturing as it signs its first monoclonal antibody (mAb) development and manufacture agreement for a European biopharma.
Agilent Technologies has officially separated its biopharma service offerings from its electric measurement group to create two separate companies, the life science portion of which is expected to bring in about $3.9B in FY2013.
A new platform to help biopharma companies discover antibodies is also helping them go after more difficult targets and earn more collaborations with top biopharma companies.
The US Defense Advanced Research Projects Agency (DARPA) has awarded MIT’s Biomanufacturing Research Program (BioMAN) a $10.4 million grant from to develop devices and techniques to more rapidly produce biologics.
EMD Millipore on Tuesday launched a new protein A chromatography media to help biopharma manufacturers purify monoclonal antibodies, as well as new prepacked chromatography columns.
Merck Millipore has launched a new range of depth filters that it claims overcome the shortcomings of traditional techs and clear a path to successful downstream clarification.
Cambridge Research Biochemicals (CRB) has licensed rights to a system that – it claims – will let biopharmas identify the best delivery peptides more quickly.
The updated draft guidance calls for fully validated bioanalytical methods for any pivotal studies used to obtain approval or labelling, though less validation may be sufficient for a sponsor’s internal decision making.
New European GDP guidance has led Sonoco to launch a series of shippers to store and transport biopharmaceuticals whilst ensuring an unbroken cold chain.
Cytotoxics will be a key growth opportunity for third-party manufacturers as biopharma increases its injectables outsourcing over the next few years, an industry report has predicted.
Roche has agreed to research, develop and commercialize Inovio Pharmaceuticals' vaccine delivery tech as well as its multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.
The US FDA approval of the new quadrivalent flu vaccine in June has not quite given manufacturers enough time to meet demand expectations, as production time can take up to about six months.
The team behind a new Malaysian biotechnology hub – the Bio-XCell Biotechnology Park - has launched a new package designed to attract biomanufacturers.
Bioreliance has doubled the space for clients to conduct their downstream bioprocessing studies with the opening of its new US Clearance Services Laboratories in Rockville, Maryland.
Making germ warfare weapons is banned under the Biological Weapons Convention (BWC) and there is no evidence signatories or even countries led by any of the World’s crackpot dictators/freedom fighters* are producing them.
US acceptance of biosimilars is “not a question of if, only of when,” according to Hospira which received a European Commission (EC) OK of its Remicade copycat yesterday.
A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.
The $165bn biopharma market is expected to grow by about 15% annually, driven largely by increasing revenue growth from recombinant monoclonal antibodies (mAbs), according to a recent report.
Horizon Discovery has licensed a zinc finger nuclease (ZFN) technology from Sigma-Aldrich and says the combination with its own platform will be “a big step forward in gene editing.”
Biopharma researchers will be able to use a new technology to explore biomarkers and pathways with more sensitivity and precision to create new diagnostics and improved oncology, neurology, cardiology and other therapies.
Bioreliance has launched an updated version of its mutagenicity service after conducting studies that confirmed its Big Blue Mouse assay still meets OECD standards.
Baxter and Coherus Biosciences have become the latest firms to try and develop a biosimilar version of the RA treatment Enbrel in a new collaboration announced this week.
Mitsubishi Tanabe Pharma (MTPC) is closer to adding two plant-based expression techs to its manufacturing arsenal after Medicago shareholders back its takeover bid.
Pall Corporation says it will continue to invest in single-use systems after reporting substantially higher growth in sales compared to stainless steel systems for the 2013 FY.
Eli Lilly has extended its collaboration with Immunogen to use its antibody-drug conjugate (ADC) technology for development of a specific antigen target.
Rani Therapeutics announced Wednesday that it has closed its Series B round of funding after pulling in more than $10m from Google Ventures, InCube Ventures and VentureHealth, a healthcare crowdfunding portal.
Biotech company Haplogen and the Center for Molecular Medicine of the Austrian Academy of Sciences this week released the largest collection of human cell lines that are deficient for single genes.
Mass spec, chromatography and analytical tech firm Waters has started its search for a new CEO based on the assumption it will remain independent and keep the same growth strategy.
As California approves a Bill constraining biosimilar substitution, the US FDA says it is concerned at efforts to undermine strict federal legislation already in place.
Investors on Tuesday seemed a little less sure of biopharma behemoth Amgen’s decision to purchase cancer specialist Onyx for more than $10B over the weekend.
The new UK biomanufacturing hub will help BioPharmas cut costs and let those developing novel biodrugs assess manufacturability according to the Centre for Process Innovation (CPI).
A third Novartis biopharmaceutical has received breakthrough designation status from the FDA allowing ‘fast-track’ development and review without compromising safety, the company says.
Stemcell Technologies will use BioLife Solutions’ cryopreservation media to ship its new range of stem cell based products under an expanded agreement.
Large arrays of identical nanosensors could improve MAb production, identify glycosylation and pinpoint the best cell lines for biomanufacturing say US researchers.
Biomanufacturing is offsetting a decline in Ireland's small molecule industry caused by the patent cliff and cheaper manufacturing options in the East say industry groups.
Alexion Pharma International has recalled a single lot of its monoclonal antibody (MAb) orphan drug Soliris due to the presence of visible particles in a limited number of vials.
Mammalian cell culture know-how and location won Rentschler Biotechnologie its new anticancer MAb manufacturing deal according Austrian BioPharma Apeiron Biologics.